MedTrace Logo

A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

NCT03814291 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-04-17

No results posted yet for this study

Summary

This study is designed for single-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single intravitreal injection of IBI302 in patients with wet AMD.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

IBI302

0.05mg/eye;Intraocular injection

DRUG

IBI302

0.15mg/eye;Intraocular injection

DRUG

IBI302

0.5mg/eye;Intraocular injection

DRUG

IBI302

1mg/eye;Intraocular injection

DRUG

IBI302

2mg/eye;Intraocular injection

DRUG

IBI302

4mg/eye;Intraocular injection

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-15
Primary Completion
2020-03-05
Completion
2020-04-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03814291 on ClinicalTrials.gov